Establishment Labs (NASDAQ:ESTA) Trading 7.2% Higher – Here’s What Happened

Establishment Labs Holdings Inc. (NASDAQ:ESTA) shares were up 7.2% on Friday . The company traded as high as $81.18 and last traded at $81.02. 112,510 shares changed hands during mid-day trading, a decline of 80% from the average session volume of 553,757 shares. The stock had previously closed at $75.59.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Citigroup upgraded shares of Establishment Labs from a “neutral” rating to a “buy” rating and set a $92.00 price objective on the stock in a research report on Thursday. TD Cowen upped their price objective on Establishment Labs from $95.00 to $117.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. BTIG Research increased their price objective on Establishment Labs from $96.00 to $103.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Mizuho increased their price objective on Establishment Labs from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a report on Wednesday, June 24th. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Establishment Labs has an average rating of “Moderate Buy” and a consensus target price of $100.25.

Establishment Labs Stock Performance

The company has a debt-to-equity ratio of 16.82, a quick ratio of 1.91 and a current ratio of 2.96. The company has a market cap of $2.39 billion, a PE ratio of -61.24 and a beta of 1.07. The business’s 50-day moving average is $86.69 and its 200 day moving average is $74.54.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.05). The business had revenue of $67.54 million for the quarter, compared to analysts’ expectations of $65.79 million. Establishment Labs had a negative net margin of 15.82% and a negative return on equity of 205.79%. The business’s quarterly revenue was up 31.7% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.57) earnings per share. On average, equities research analysts predict that Establishment Labs Holdings Inc. will post -1.16 EPS for the current fiscal year.

Hedge Funds Weigh In On Establishment Labs

Large investors have recently bought and sold shares of the stock. KBC Group NV bought a new position in shares of Establishment Labs in the first quarter worth approximately $28,000. Quarry LP purchased a new stake in Establishment Labs during the 3rd quarter valued at $34,000. Northwestern Mutual Wealth Management Co. purchased a new stake in Establishment Labs during the 2nd quarter valued at $43,000. Kestra Advisory Services LLC purchased a new stake in Establishment Labs during the 4th quarter valued at $47,000. Finally, Osaic Holdings Inc. grew its holdings in Establishment Labs by 900.0% in the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after acquiring an additional 1,800 shares during the last quarter. 72.91% of the stock is owned by hedge funds and other institutional investors.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.